Search

Crovalimab

[L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [L50933] Unlike other complement inhibitors previously approved for PNH, crovalimab uses a mechanism called anti-C5 sequential monoclonal antibody recycling technology that allows the drug to bind to

Omaveloxolone

[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. … [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition.

Ferrous glycine sulfate

PF-05230907

PF-05230907 is a recombinant activated Factor X variant.

Felodipine

In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent

Lunsotogene parvec

Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic

Clove oil

The antioxidant and antimicrobial activity of clove is higher than that of many fruits, vegetables, and other spices [A33133]. … The FDA categorizes clove oil as generally recognized as safe (GRAS) for use in dental cement or as a food additive [F108].

Estrone sulfate

types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men

Silicon dioxide

Silicon dioxide, or silica, is an oxide of silicon with the chemical formula SiO2.

Brotizolam

Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. … Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).